BioSpace News Archive

Luminex Corporation (Nasdaq:LMNX) (the “Company”), today announced that its board of directors declared a cash dividend for the third quarter of 2018 of $0.06 per share of common stock payable on October 12, 2018 to stockholders of record as of the close of business September 21, 2018.

In recognition of two new USPTO patents for the LANAP® and LAPIP™ protocols (US patent 9943379 B2 and US patent 9597160 B1, respectively), and the value they bring to dentists and their patients receiving treatment, Millennium Dental Technologies, Inc. is announcing an increase in the investment for acquiring the PerioLase® Periodontal Package

The most recent edition of the Patented Medicine Prices Review Board’s (PMPRB) CompassRx report found that public drug plan expenditures increased by an additional 1.9% in 2016-17, following a notable growth of 10.8% in 2015-16, reaching a total of $10.7 billion.

PPG (NYSE: PPG) today announced that one of its leading scientists for energy storage solutions will discuss recent advances in electrode binders and coatings for automotive lithium-ion batteries during The Battery Show North America 2018, which will be held Sept. 11-13 in Novi, Michigan.

Pet health, vet health; WellHaven was founded on the principle that you can’t have one without the other. A new partnership with CUBEX--the industry leader in inventory management solutions--elevates WellHaven Pet Health hospital operating efficiency, increases practice safety, helps teams succeed, and ultimately, improves quality of life for pets and veterinarians.

This replaces the announcement made at 06:45 pm CEST on 09/11/2018 due to the following corrections: correction in the title.

Regen BioPharma Inc. has identified a series of small molecule drugs that inhibit NR2F6.

Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London.

Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises, today announced financial results for the second quarter and first half of fiscal 2018, which ended July 31, 2018.

Aerie Pharmaceuticals, Inc., (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Robert Finan, Director of Finance